СИСТЕМНЕ ХІМІОТЕРАПЕВТИЧНЕ ЛІКУВАННЯ ХВОРИХ З МЕТАСТАЗАМИ РАКУ ГРУДНОЇ ЗАЛОЗИ У ГОЛОВНИЙ МОЗОК
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-2.16249Ключові слова:
метастази у головний мозок, рак грудної залози, прогностичні фактори, ефективність системної протиракової терапії, гематоенцефалічний бар’єр.Анотація
Резюме. Метастази солідних пухлин у головний мозок є найбільш поширеними внутрішньочерепними неоплазмами у дорослих. Наведено стислий огляд ролі гематоенцефалічного бар’єру в патогенезі метастазів раку грудної залози у головний мозок та ефективності системної протиракової терапії у лікуванні цієї категорії хворих.
Посилання
Liubota R, Vereshchako R, Anikusko M, Liubota I. Management of brain metastases from solid tumors. In: Hamza A, Salem N, Eds. Cancer Management and Therapy. IntechOpen, 2018. DOI: 10.5772/intechopen.75447. Available from: https://www.intechopen.com/books/cancer-management-and-therapy/management-of-brain-metastases-from-solid-tumors
Griguolo G, Jacot W, Kantelhardt E, et al. External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases: a multicentric European experience. Breast 2017; 37: 36–41.
Subbiah IM, Lei X, Weinberg JS, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol 2015; 33: 2239–45.
Liubota R., Cheshuk V., Vereshchako R. et al. The impact of locoregional treatment on survival of patients with primary metastatic breast cancer. Exp Oncol 2017; 39: 75–7.
Wilhelm I, Fazakas C, Molnar K, et al. Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases. J Cereb Blood Flow Metab 2018; 38: 563–87.
Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 2013; 7: 27–34.
Gomez-Zepeda D, Taghi M, Scherrmann JM, et al. ABC Transporters at the blood-brain interfaces, their study models, and drug delivery implications in gliomas. Pharmaceutics 2019; 12: 20.
Lin X., DeAngelis L. M. Treatment of brain metastases. J Clin Oncol 2015; 33: 3475–84.
Fong CW. Permeability of the blood-brain barrier: molecular mechanism of transport of drugs and physiologically important compounds. J Membr Biol 2015; 248: 651–69.
Teleanu DM, Negut I, Grumezescu V, et al. Nanomaterials for drug delivery to the central nervous system. Nanomaterials (Basel) 2019; 9: E371.
Wu D, Si M, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: Current state of the art. Int J Nanomed 2017; 12: 5879–92.
Lombardi G, Di Stefano AL, Farina P, et al. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat Rev 2014; 40: 951–9.
Seoane J, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Mol Oncol 2014; 8: 1120–31.
Addeo R, Sperlongano P, Montella L, et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 2012; 70: 603–9.
Cortés J, Rugo HS, Awada A, et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat 2017; 165: 329–41.
Siena, S, Crino L, Danova M, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 2010; 21: 655–61.
Naskhletashvili DR, Gorbunova VA, Bychkov MB, et al. Gemcitabine plus cisplatin in patients with heavily pretreated breast cancer with brain metastases. J Clin Oncol 2010; 28: Suppl abstr 1125.
Erten C, Demir L, Somali I, et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev 2013; 14: 3711–7.
Jacot W, Gerlotto-Borne MC, Thezenas S, et al. Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer 2010; 10: 1–10.
Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis. Eur J Cancer 2017; 84: 141–8.
Yap YS, Cornelio GH, Devi BC. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer 2012; 107: 1075–82.
Freedman RA, Gelman RS, Melisko ME, et al. TBCRC 022: phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). J Clin Oncol 2017; 35: Suppl abstr 1005.
Fabi A, Alesini D, Valle E, et al. T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer. Breast 2018; 41: 137–43.
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2023 Експериментальна онкологія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
